Appendix Table A5.

Distribution of Change in Fellow-eye Visual Acuity from Baseline to Follow-up Visits by Treatment Group.

	4 weeks				8 weeks
	Binocular Treatment		Continued Spectacles		Binocular Treatment		Continued Spectacles
	N	%	N	%	N	%	N	%
Per Group (N)	88		84		86		84
Change in fellow-eye VA from baseline
≥ 3 logMAR lines better	0	0%	2	2%	1	1%	1	1%
2 logMAR lines better	2	2%	2	2%	7	8%	5	6%
1 logMAR line better	20	23%	23	27%	25	29%	21	25%
0 logMAR line	50	57%	44	52%	40	47%	40	48%
1 logMAR line worse	14	16%	8	10%	12	14%	17	20%
2 logMAR lines worse	2	2%	4	5%	1	1%	0	0%
≥ 3 logMAR lines worse	0	0	1	1%	0	0%	0	0%
Mean (SD) Linesa	0.1 (0.8)		0.2 (1.0)		0.3 (0.9)		0.2 (0.9)
Adjusted mean (95% CI) Linesb	0.1 (−0.1, 0.2)		0.2 (0.02, 0.4)		0.3 (0.1, 0.5)		0.2 (0.04, 0.4)
Adjusted mean difference (99% CI) Linesb		-0.1 (−0.5, 0.2)				0.1 (−0.2, 0.4)
Worsening of ≥ 2 lines from baseline	2	2%	5	6%	1	1%	0	0%
Difference (99% CI)c	-4% (−15%, 6%)				1% (−6%, 9%)

CI = confidence interval; logMAR = logarithm of minimum angle of resolution; SD = standard deviation; VA = visual acuity.

^aPositive values indicate improvement in fellow-eye visual acuity from baseline.

^bAnalysis of covariance model adjusting for baseline fellow-eye visual acuity was used to estimate the mean change in fellow-eye visual acuity within each treatment group as well as the treatment group difference (positive values favor the binocular treatment group) in the mean change in fellow-eye visual acuity from baseline to 4 weeks (P = .26) and to 8 weeks (P = .41).

^cBarnard’s exact test was used to compare the proportion of participants with worsening of ≥ 2 lines in fellow-eye visual acuity from baseline to 4 weeks (P = .25) and to 8 weeks (P = .52) between treatment groups.